Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - September 21, 2016) - AIM™ vector system is a novel AAV-based vector technology platform that may target CNS and other tissues with increased efficiency...
-
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 16, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing gene and plasma-based...
-
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - September 15, 2016) - Preclinical efficacy data demonstrated significant benefits leading to restoration of SGSH activity and reduction of...
-
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 08, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)EB-101 (gene-corrected skin grafts) has demonstrated promising clinical efficacy in...
-
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 07, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing gene and plasma-based...
-
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 01, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing gene and plasma-based...
-
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 29, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO): Low-dose cohort (n=3) enrollment completed for ongoing study to evaluate ABO-102 (AAV-SGSH),...
-
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 16, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene and plasma-based...
-
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 09, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) Collaboration will focus on gene therapy treatments for epidermolysis bullosa (EB) EB-101, an...
-
NEW YORK, NY and CLEVELAND, OH--(Marketwired - August 04, 2016) - Abeona Therapeutics, Inc. (NASDAQ: ABEO) Approval of clinical trial for ABO-102 (AAV-SGSH) in European Union marks 3rd regulatory...